Document Detail


Lack of Direct Association between EGFR Mutations and ER Beta Expression in Lung Cancer.
MedLine Citation:
PMID:  21498706     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Positive expression of estrogen receptor (ER) beta is correlated with a favorable prognosis for patients with epidermal growth factor receptor (EGFR) mutations and predicts a good clinical outcome for patients with lung cancer after treatment with an EGFR-tyrosine kinase inhibitor (TKI), suggesting that it may be a candidate surrogate marker. The molecular mechanism underlying the apparent link between EGFR mutations and ER beta expression in lung cancer cell lines was investigated.
MATERIALS AND METHODS: Four different human lung cancer cell lines were used, including one with an exon19 delE746-A750, one with a substitution of Leu for Arg at codon 858 in exon 21 (L858R), one with a L858R+ threonine-to-methionine mutation at codon 790 of EGFR (T790M) and one with wild-type EGFR. The EGFR mutations were investigated by direct sequencing. The expression levels of ER beta in the cell lines, in tumors from SCID mice and in primary human tissue specimens were evaluated by immunohistochemistry. Cell growth was compared after treatment with 17-beta-estradiol. The proliferative activity following knockdown of ER beta by siRNA was also examined. Furthermore, the cell inhibition assay was performed for cells treated with gefitinib after knockdown of ER beta. To investigate the relevant pathways for ER beta, the expression of apoptosis-related molecules was evaluated by Western blotting analysis.
RESULTS: All the cell lines showed positive expression of ER beta, the cancer cells from SCID mice, and the original primary tumors showed positive expression of ER beta. All of the cell lines revealed a similar proliferative pattern, regardless of the presence of EGFR mutations. Although the suppression of ER beta slightly increased the proliferative activity, no statistically significant effect on proliferation was observed in any of the cell lines. Moreover, no significant changes in any cell signaling or apoptosis-related molecules were observed following ER beta knockdown.
CONCLUSION: A direct association between EGFR mutations and ER beta expression in lung cancer cell lines is lacking. Further investigation will be necessary to clarify the role of the ER in the EGFR signaling pathway.
Authors:
Takamitsu Onitsuka; Hidetaka Uramoto; Fumihiro Tanaka
Related Documents :
20059996 - Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human ret...
15110396 - Nitric oxide and bcnu chemoresistance in c6 glioma cells: role of s-nitrosoglutathione.
7475946 - Pentamidine does not interfere with nitrite formation in activated raw 264.7 macrophage...
11173976 - Cyp2e1-dependent toxicity and up-regulation of antioxidant genes.
17660326 - Exposure of differentiated airway smooth muscle cells to serum stimulates both inductio...
23506616 - Houttuynia cordata thunb extract modulates g0/g1 arrest and fas/cd95-mediated death rec...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  31     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-04-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  855-60     Citation Subset:  IM    
Affiliation:
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. hidetaka@med.uoeh-u.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines.
Next Document:  The endothelin axis in the metastatic process of colon carcinoma.